Liang Chudan, Qian Jun, Liu Linna
Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, China.
Key Laboratory of Tropical Disease Control (Sun Yat-sen University), Ministry of Education, Guangzhou 510030, China.
Biosaf Health. 2022 Dec;4(6):376-385. doi: 10.1016/j.bsheal.2022.11.001. Epub 2022 Nov 9.
Monkeypox is a zoonotic disease caused by the monkeypox virus (MPXV), which is a potential biological warfare agent of bioterrorism and poses the greatest threat to the world's public biosafety and health after variola virus (VARV). While the coronavirus disease 2019 (COVID-19) pandemic has not ended yet, monkeypox is spreading menacingly. The first case of monkeypox in a nonendemic country was confirmed on May 6, 2022, while the first imported case from Asia was found on June 21. There were more than 16 thousand reported cases as of July 23, the day the World Health Organization (WHO) declared the global monkeypox outbreak a public health emergency of international concern (PHEIC) at the same level as smallpox and COVID-19; while there were more than 53 thousand cases as of September 1. Therefore, we will propose relevant biosafety prevention and control strategies after analyzing the etiology of the 2022 multi-country monkeypox outbreak from the biological feature, transmissibility, epidemic, and variability of MPXV.
猴痘是由猴痘病毒(MPXV)引起的一种人畜共患病,该病毒是生物恐怖主义的潜在生物战剂,对世界公共生物安全和健康构成仅次于天花病毒(VARV)的最大威胁。在2019冠状病毒病(COVID-19)大流行尚未结束之际,猴痘正在肆虐蔓延。2022年5月6日,非流行国家确诊首例猴痘病例,6月21日发现首例来自亚洲的输入性病例。截至7月23日,报告病例超过1.6万例,当日世界卫生组织(WHO)宣布全球猴痘疫情构成国际关注的突发公共卫生事件(PHEIC),与天花和COVID-19处于同一级别;截至9月1日,病例数已超过5.3万例。因此,我们将从MPXV的生物学特性、传播性、流行性和变异性等方面分析2022年多国猴痘疫情的病原学,进而提出相关生物安全防控策略。